Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting Four Tumour-associated Antigens in Patients With Advanced Melanoma

Trial Profile

Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting Four Tumour-associated Antigens in Patients With Advanced Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs RBL 001/RBL 002/RBL 003/RBL 004 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man
  • Sponsors BioNTech
  • Most Recent Events

    • 09 Sep 2017 Preliminary results of more than 20 patients from this trial, presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
    • 05 Apr 2017 Safety and tolerability results in first 15 patients treated as of January 2017 presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 07 Mar 2017 According to a BioNTech media release, interim data from this trial will be presented at the 2017 Annual Meeting of the American Association for Cancer Research (AACR).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top